J
James A. Retsema
Researcher at Pfizer
Publications - 40
Citations - 2863
James A. Retsema is an academic researcher from Pfizer. The author has contributed to research in topics: Azithromycin & Antibacterial agent. The author has an hindex of 20, co-authored 40 publications receiving 2808 citations. Previous affiliations of James A. Retsema include Yeshiva University.
Papers
More filters
Journal ArticleDOI
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.
James A. Retsema,Arthur E. Girard,W Schelkly,Mary Manousos,M Anderson,G. M. Bright,R Borovoy,L. A. Brennan,Rachel J. Mason +8 more
TL;DR: The macrolide antibiotic azithromycin showed a significant improvement in potency against gram-negative organisms compared with erythromycin while retaining the classic erystromycin spectrum.
Journal ArticleDOI
CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological Characterization
TL;DR: CP-45,899 is an irreversible inhibitor of several bacterial penicillinases and cephalosporinases in the presence of low concentrations of the compound as discussed by the authors.
Journal ArticleDOI
Molecular cloning and functional analysis of a novel macrolide‐resistance determinant, mefA, from Streptococcus pyogenes
Joanna Clancy,J.W. Petitpas,Fadia Dib-Hajj,Wei Yuan,Melissa Cronan,Ajith V. Kamath,Jay M. Bergeron,James A. Retsema +7 more
TL;DR: Physiological studies of the cloned determinant, which has been named mefA for macrolide efflux, provide evidence for its mechanism of action in host bacteria, with results consistent with a hypothesis that the gene encodes a novel antiporter function which pumps erythromycin out of the cell.
Journal ArticleDOI
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.
Arthur E. Girard,Dennis Girard,Arthur R. English,Thomas D. Gootz,C R Cimochowski,J A Faiella,Suzanne L. Haskell,James A. Retsema +7 more
TL;DR: The pharmacokinetic advantage of azithromycin over erythromycin in half-life was clearly demonstrated in prophylactic treatment of an acute mouse model of S. aureus infection.
Journal ArticleDOI
Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.
G. Michael Bright,Arthur Adam Nagel,Jon Bordner,Desai Kishor A,Joseph DiBrino,Jolanta Nowakowska,Lawrence A. Vincent,Richard M. Watrous,Frank C. Sciavolino,Arthur R. English,James A. Retsema,M Anderson,Lori Brennan,Roberta J. Borovoy,Caroline R. Cimochowski,J A Faiella,Arthur E. Girard,Dennis Girard,Carol Herbert,Mary Manousos,Rachel J. Mason +20 more
TL;DR: The overall in vitro/in vivo performance of N-methyl, C- 4'' epimers 3a and 9; and C-4'' amine 11 identify these compounds as the most interesting erythromycin A-superior agents.